Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | AGT | P01019 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404889 | 1.00 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7ALDH1A1 | |
| SCHEMBL7196989 | 0.91 | AGTR1 (0.41) | AGTR1AGTR2P2RX7ALDH1A1TRPA1 | |
| SCHEMBL8907583 | 0.90 | AGTR1 (0.51) | AGTR1AGTR2AGTP2RX7 | |
| SCHEMBL7384556 | 0.89 | AGTR1 (0.42) | AGTR1AGTR2AGTP2RX7 | |
| SCHEMBL29931185 | 0.89 | AGTR1 (0.44) | AGTR1AGTR2AGTP2RX7ALDH1A1 | |
| SCHEMBL588221 | 0.89 | AGTR1 (0.44) | AGTR1AGTR2AGTP2RX7ALDH1A1 | |
| SCHEMBL9024777 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2AGTP2RX7TSHR | |
| SCHEMBL30316147 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2AGTP2RX7TSHR | |
| SCHEMBL8246839 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7ALDH1A1 | |
| SCHEMBL4246354 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2AGTP2RX7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163391-B | Candesartan intermediate and preparation method of Candesartan | 迪嘉药业集团股份有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114733575-A | Palladium-loaded molecular sieve catalyst and preparation method and application thereof | 浙江天宇药业股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114733526-A | Nickel-loaded porous carbon material catalyst and preparation method and application thereof | 浙江天宇药业股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114163391-A | Candesartan intermediate and preparation method of candesartan | 迪嘉药业集团有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-113717118-B | Synthesis process of valsartan | 安徽美诺华药物化学有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113717118-A | Synthesis process of valsartan | 安徽美诺华药物化学有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-113666881-A | Synthesis method of mutagenic azide impurities in tetrazole sartan bulk drugs | 河南华商药业有限公司 | 2021-11-19 | — | — | CN | claimed |
| EP-3083582-B1 | A NEW PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL | FARMA GRS D O O (SI) | 2019-06-26 | — | — | EP | claimed |
| EP-1910343-B1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | KRKA (SI) | 2014-10-29 | — | — | EP | claimed |
| EP-2173741-B1 | A PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | LEK PHARMACEUTICALS (SI) | 2013-10-02 | — | — | EP | claimed |
| US-7038060-B2 | Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-05-02 | — | — | US | claimed |
| EP-1622882-A1 | A METHOD OF PREPARATION OF N -(1-OXOPENTYL)- N-[[ 2-(1TETRAZOL-5-y1) [1,1 -BIPHENYL]-4-y1 METHYL] -L-VALINE (VALSARTAN) | ZENTIVA, A.S. (CZ) | 2006-02-08 | — | — | EP | claimed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | claimed |
| US-20050176794-A1 | Novel synthesis of irbesartan | TEVA PHARMACEUTICALS USA, INC. | 2005-08-11 | — | — | US | claimed |
| EP-1546135-A2 | NOVEL SYNTHESIS OF IRBESARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-06-29 | — | — | EP | claimed |
| WO-2005049602-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | claimed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004101534-A1 | A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN) | ZENTIVA, A. S. (CZ) | 2004-11-25 | — | — | WO | claimed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| WO-2004007482-A2 | NOVEL SYNTHESIS OF IRBESARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | AGTR1, AGTR2, TEK | AGTR1 1/4885AGTR2 2/4885AGT 11/4885 |
| US-20050176794-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885AGT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.